Biotechnology

Damora Therapeutics

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

Actelis Networks

Acurx Pharmaceuticals

Golden Sun Tech

XCF Global

Tradr 2X Long NVTS Daily ETF

Commercial Vehicle

Sagtec Global

Beachbody

Defiance Daily Target 2X Long HIMS ETF

Ocugen

GLTO

ICLR

ARKG

SBIO

DMRA

In Thursday's intraday session, SCWorx (WORX) saw a significant gain of 52.7%, reaching $0.28, while NovoCure (NVCR) rose by 27.19% to $13.36. Other notable gainers included Karyopharm Therapeutics (KPTI) up 25.88%, Galecto (GLTO) up 24.22%, and SS Innovations (SSII) up 20.18%. Conversely, Strata Skin Sciences (SSKN) experienced a sharp decline of 64% to $0.43, followed by Quince Therapeutics (QNCX) down 49.45%, and BioRestorative Therapies (BRTX) down 43.58%. Icon (ICLR) and Seres Therapeutics (MCRB) also saw significant losses.

benzinga_article

Proshares Ultra Nasdaq Biotech

Galecto

ICON

SPDR S&P Biotech

Seres Therap

Health Care Select Sector SPDR

SS Innovations

Karyopharm Therap

Ark Genomic Revolution ETF

VanEck Biotech ETF

iShares US Pharma

ALPS Medical Breakthrough

iShares Genomics Immunology and Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

VG Health

iShares Biotechnology ETF

Biorestorative Therapies

iShares Global Healthcare

Novocure

Invesco Nasdaq Biotechnology ETF

Strata Skin Sciences

Quince Therapeutics

Invesco Biotechnology & Genome ETF

iShares US Healthcare Providers

SPDR S&P Health Equip

SCWorx

12 Health Care Stocks Moving In Thursday's Intraday Session

MRNA

In Wednesday's pre-market session, Quince Therapeutics (QNCX) saw a significant gain of 62.2%, reaching $0.86, while Neuronetics (STIM) rose by 25.34% to $1.83. Other gainers included Talphera (TLPH) up 19.6% to $1.00 and Hinge Health (HNGE) up 11.92% to $36.99. Conversely, Upstream Bio (UPB) fell 28.1% to $19.99, followed by Abpro Holdings (ABP) down 16.77% to $1.39. Moderna (MRNA) also declined by 10.07% to $37.77. The Q4 earnings reports influenced these movements.

Moderna

Hinge Health

SPDR S&P Health

Talphera

Neuronetics

Upstream Bio

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Biopharmaceutical company Galectosaw its shares drop 6.8% to $20.05 in premarket trading following a $275 million equity raise. The company sold approximately 14.5 million shares at $19 each, an 11.7% discount. Proceeds will fund preclinical studies, clinical trials, and R&D. Additionally, CEO Hans T. Schambye has stepped down, with COO Sherwin Sattarzadeh appointed as interim CEO. Despite a recent decline, all analysts covering the stock remain bullish, with price targets ranging from $36 to $46.

Reuters

BUZZ-Biopharma co Galecto drops after $275 mln stock sale

Galecto, Inc. has priced its underwritten public offering of 14,473,685 shares of common stock at $19.00 per share, aiming to raise approximately $275 million. The offering includes a 30-day option for underwriters to purchase an additional 2,171,052 shares. The offering is expected to close around February 12, 2026, subject to customary conditions. Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are the joint book-running managers. This announcement follows the filing of an effective shelf registration statement with the SEC.

StockTitan

Galecto Announces Pricing of $275 Million Underwritten Public Offering | GLTO Stock News

Galecto Inc. held a special shareholder meeting on February 9, 2026, where stockholders approved the company's redomestication to the Cayman Islands and the adoption of new memorandum and articles of association. Additionally, the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan were also approved.

Direxion S&P Biotech Bear 3X

Galecto Inc. Held Special Shareholder Meeting

Galecto Inc. has filed an initial beneficial ownership statement (Form 3) with the U.S. SEC, listing Sherwin Sattarzadeh, the Chief Operating Officer, as the beneficial owner. The filing is accessible through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

Galecto Inc. Files Initial Beneficial Ownership Statement for Chief Operating Officer Sherwin Sattarzadeh

Galecto Inc. has acquired Damora Therapeutics to enhance its portfolio with therapies for mutant CALR-driven myeloproliferative neoplasms (MPNs). The lead program is a subcutaneous anti-mutCALR monoclonal antibody targeting essential thrombocythemia (ET) and myelofibrosis (MF). Clinical data suggest potential for disease modification and high response rates, with self-administration via an autoinjector every two weeks. The therapy aims to differentiate from current standards and late-stage competitors, emphasizing ease of use and long-term adherence.

Galecto Inc. Unveils Mutant CALR Antibody Program Targeting Myeloproliferative Neoplasms

Galecto, Inc. has successfully acquired Damora, marking a significant milestone in its strategic expansion. This acquisition, along with new senior leadership, aims to enhance Galecto's position in the biopharmaceutical sector and expedite its pipeline programs, including expected IND submissions for DMR-001 and DMR-002 in 2026. The company views these developments as the start of a new chapter focused on delivering transformative therapies for patients with blood cancers.

Galecto Acquires Damora and Expands Leadership Team

Lori Firmani, CFO of Galecto Inc., reported the disposal of common shares. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. Galecto Inc. published the original content via EDGAR on January 06, 2026, and is responsible for the information.

Galecto CFO Lori Firmani Reports Disposal of Common Shares

Galecto has appointed Sherwin Sattarzadeh as chief operating officer, effective January 5, 2026, as part of its strategy to enhance leadership. The company also issued a warrant to Paramora Holding LLC for 628,302 shares at $23.01 each, linked to its antibody discovery agreement. Analysts rate GLTO stock as a Hold with a $31.00 price target, reflecting weak fundamentals but positive technical momentum. Galecto focuses on drug development in hematology, oncology, and rare diseases, with a market cap of $33.96M.

Tip Ranks

Galecto appoints new chief operating officer, enhances leadership

Galecto Inc. has issued a warrant to Paramora Holding LLC for the purchase of 628,302 shares of common stock at an exercise price of $23.01 each. This issuance is part of an agreement with Paragon Therapeutics, Inc. and Paramora. The warrant will expire ten years from the issue date and was made under the exemption from registration requirements of the Securities Act of 1933, involving a single accredited investor.

Galecto Issues Warrant for 628,302 Shares to Paramora at $23.01 Each

Galecto Inc. has appointed Sherwin Sattarzadeh as COO and Dr. Becker Hewes as CMO, effective January 5, 2026. Both bring extensive experience in hematology and oncology drug development as the company prepares to advance its lead candidate, DMR-001, into clinical trials.

Galecto Inc. Appoints Sherwin Sattarzadeh as COO and Becker Hewes as CMO

Galecto Inc's (NYSE:GLTO) short interest has increased by 7.93%, with 181,000 shares sold short, representing 11.7% of available trading shares. It would take traders an average of 1.15 days to cover these short positions. Rising short interest can indicate bearish sentiment among investors, while a decrease may suggest bullish sentiment. Galecto's short interest is higher than its peer group average of 4.98%. This trend does not guarantee a stock price decline but warrants attention from traders.

Is the Market Bullish or Bearish on Galecto Inc?

Ownership	%Owned	Share Chg	Report Date
Fairmount Funds Management LLC	14.46%	No Change	09/02/2026
VR Management, LLC	5.98%	No Change	09/02/2026
Ikarian Capital, LLC	0.56%	50.00 K	28/02/2026
FMR LLC	0.4%	No Change	31/12/2025
Julianne Bruno	0.23%	129.00 K	09/02/2026
Jain Global LLC	0.2%	No Change	31/12/2025
Paragon Therapeutics, Inc.	0.2%	No Change	01/12/2025
Panorama Holdings, LLC	0.2%	No Change	01/12/2025
Remedium Capital Partners, Llc	0.2%	No Change	31/12/2025
Point72 Asset Management, L.P.	0.18%	No Change	31/12/2025

Damora Therapeutics(DMRA.US)

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BUZZ-Biopharma co Galecto drops after $275 mln stock sale

Galecto Announces Pricing of $275 Million Underwritten Public Offering | GLTO Stock News

Galecto Inc. Held Special Shareholder Meeting